EXACT Sciences Co. (EXAS) Given Average Rating of “Buy” by Brokerages

Share on StockTwits

Shares of EXACT Sciences Co. (NASDAQ:EXAS) have earned an average rating of “Buy” from the sixteen analysts that are presently covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation, ten have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $88.20.

Several research firms have commented on EXAS. Benchmark restated a “hold” rating on shares of EXACT Sciences in a research note on Wednesday, September 5th. Cowen boosted their target price on EXACT Sciences from $65.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 5th. Craig Hallum boosted their target price on EXACT Sciences from $54.00 to $74.00 and gave the stock a “buy” rating in a research note on Thursday, August 23rd. BidaskClub cut EXACT Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 26th. Finally, Zacks Investment Research raised EXACT Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, August 21st.

Shares of EXAS stock traded down $1.46 during trading on Monday, reaching $74.62. The company’s stock had a trading volume of 1,932,975 shares, compared to its average volume of 2,147,434. The company has a debt-to-equity ratio of 0.94, a quick ratio of 11.72 and a current ratio of 12.08. The stock has a market capitalization of $9.28 billion, a P/E ratio of -75.37 and a beta of 1.21. EXACT Sciences has a 1-year low of $37.36 and a 1-year high of $81.22.

EXACT Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Tuesday, October 30th. The medical research company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. The firm had revenue of $118.29 million during the quarter, compared to analysts’ expectations of $109.33 million. EXACT Sciences had a negative net margin of 35.83% and a negative return on equity of 20.18%. The business’s quarterly revenue was up 63.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.23) earnings per share. On average, research analysts forecast that EXACT Sciences will post -1.53 EPS for the current fiscal year.

In related news, insider Graham Peter Lidgard sold 58,000 shares of the company’s stock in a transaction that occurred on Monday, October 8th. The stock was sold at an average price of $69.36, for a total value of $4,022,880.00. Following the completion of the transaction, the insider now directly owns 204,684 shares of the company’s stock, valued at $14,196,882.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider D Scott Coward sold 2,190 shares of the company’s stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $79.51, for a total value of $174,126.90. The disclosure for this sale can be found here. In the last quarter, insiders have sold 218,255 shares of company stock valued at $15,791,740. Insiders own 3.20% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Cornerstone Wealth Management LLC acquired a new position in shares of EXACT Sciences in the 2nd quarter valued at $182,000. Chicago Partners Investment Group LLC boosted its stake in EXACT Sciences by 47.6% in the third quarter. Chicago Partners Investment Group LLC now owns 3,100 shares of the medical research company’s stock valued at $191,000 after acquiring an additional 1,000 shares in the last quarter. Hartford Investment Management Co. acquired a new position in EXACT Sciences in the second quarter valued at $202,000. Fulton Bank N.A. acquired a new position in EXACT Sciences in the third quarter valued at $208,000. Finally, Alps Advisors Inc. acquired a new stake in shares of EXACT Sciences in the 2nd quarter valued at about $210,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Further Reading: What is a Call Option?

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply